top of page
ÉãͼÍø_501364120_ÉîÛÚÍåÈ˲Ź«Ô°ÈÕÂä¾°É«£¨·ÇÆóÒµÉÌÓã©.jpg
Untitled.png

Yan Zou 邹晏

Graduate Student

Joint mentor: Zhenguo Wu

Division of Life Science, Hong Kong University of Science and Technology

Email:

A Bit About Me

The discovery of lymphatic vessels in the brain has opened a new avenue of research for understanding the interaction between the immune and the central nervous system. Among many exciting topics, I am mostly interested in the mysterious role of T cells in a healthy brain, as well as that in neurodegeneration where no obvious infection is noticed. In the Wu lab, I will mainly use single cell RNAseq technology, transgenic animal models, and develop novel genetic approaches to interrogate these questions. I hope my effort will uncover novel CNS regulation mechanisms, and ideally, lead to innovative therapeutics based on T cell targeting for neurodegeneration treatment.

EDUCATION AND PROFESSIONAL EXPERIENCE

  • Oct 2012 – Sep 2014 Master of Science in Molecular Bioengineering Technische Universität Dresden, Germany

  • Sep 2008 – Jun 2012 Bachelor of Engineering, major in Bioengineering China Pharmaceutical University, Nanjing, China

 

SCHOLARSHIPS AND AWARDS

  • Jan 2018 - Annual Outstanding Employee Awards of ShanghaiTech University.

  • Nov 2013 - Participated in the International Bio-Molecular Design Competition at Harvard University. Gold medal for the team project.

  •  Jul 2012 - Honor of “Excellent Graduate Student”, awarded by China Pharmaceutical University.

PUBLICATION

  • Zou Y, Liu B, Li L, Yin Q, Tang J, Jing Z, Huang X, Zhu X, Chi T. (2021) IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors. Cancer Lett. 524:121-130.

  • Tang J, Zou Y, Li L, Lu F, Xu H, Ren P, Bai F, Niedermann G, Zhu X. (2021) BAY 60-6583 enhances the antitumor function of chimeric antigen receptor-modified T cells independent of the adenosine A2b receptor. Front Pharmacol, 12:619800.

  • Hu B, Zou Y, Zhang L, Tang J, Niedermann G, Firat E, Huang X, Zhu X. (2018) Nucleofection with plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells. Hum Gene Ther, 30(4):446-458.

  • Fei JF, Knapp D, Schuez M, Murawala P, Zou Y, Pal Singh S, Drechsel D, Tanaka EM. (2016) Tissue- and time-directed electroporation of CAS9 protein-gRNA complexes in vivo yields efficient multigene knockout for studying gene function in regeneration. NPJ Regen Med, 1:16002.

bottom of page